You are now leaving AlloVir’s website.

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
yesno

You are now leaving AlloVir’s website.

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
yesno

You are now leaving AlloVir’s website.

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
yesno

You are now leaving AlloVir’s website.

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
yesno

You are now leaving AlloVir’s website.

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
yesno

You are now leaving AlloVir’s website.

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
yesno

You are now leaving AlloVir’s website.

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
yesno

You are now leaving AlloVir’s website.

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
yesno

You are now leaving AlloVir’s website.

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
yesno
Home
/
Publications

Science Founded on Unique Insights, Powered by Groundbreaking Research

A collection of research papers, scientific publications and presentations relevant to our platform, processes, and products.

Clicking on one of the links below will direct you away from AlloVir's website.

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing these links as a convenience, and these links do not imply AlloVir’s endorsement of any material on the website you are about to visit.
Title
Publication
Date
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation
Journal of Clinical Oncology
August 1, 2017
Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections
Haematologica
April 1, 2019
Mini” bank of only 8 donors supplies CMV-directed T cells to diverse recipients
Blood Advances
September 1, 2019
Infusion of Cytotoxic T Lymphocytes for the Treatment of Viral Infections in Hematopoetic Stem Cell Transplant Patients
Current Opinion Infections Diseases
August 1, 2018
Antiviral T-cell Therapy
Immunological Reviews
April 1, 2014
The publications above are provided for historical purposes only. AlloVir disavows any obligation to update the information contained in these publications after the date of their issuance.
Title
Publication / Congress
Date
195 - Economic and Clinical Burden of Respiratory Virus Infections in Allogeneic Hematopoietic Cell Transplantation Recipients
ID Week
October 21, 2020
1089 - Health Resource Utilization and Costs Associated with Multi-Virus Infection after Allogeneic Hematopoietic Cell Transplantation
ID Week
October 21, 2020
"Mini" Bank of Only 8 Donors Supplies CMV-directed T Cells to Diverse Recipients
Blood Advances
September 1, 2019
Rapid Generation of Multivirus-Specific T Lymphocytes for the Prevention and Treatment of Respiratory Viral Infections
Haematologica
April 1, 2019
Infusion of Cytotoxic T Lymphocytes for the Treatment of Viral Infections in Hematopoetic Stem Cell Transplant Patients
Current Opinion Infections Diseases
August 1, 2018
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation
Journal of Clinical Oncology
August 1, 2017
Antiviral T-cell Therapy
Immunological Reviews
April 1, 2014

The publications above are provided for historical purposes only. AlloVir disavows any obligation to update the information contained in these publications after the date of their issuance.

We Treat High-Risk Individuals

Our allogeneic, off-the-shelf virus-specific T cell (VST) therapy candidates benefit patients with T cell deficiencies including transplant recipients, immunocompromised cancer patients, the elderly, and the very young at a higher risk of the devastating consequences of viral disease.
Life-Threatening Viral Infections
Uncontrolled Viral Diseases Cause End-Organ Damage and Mortality
BK Virus
Cytomegalovirus
Adenovirus
Epstein-Bar Virus
Human Herpesvirus-6
Parainfluenza Virus
Human Metapneumovirus
Influenza Virus
Respiratory Syncytial Virus
SARS-CoV-2
Hepatitis B Virus
Human Herpesvirus-8
Bladder
Severe hemorrhagic cystitis
Urinary obstruction
Cystectomy
Brain
Severe encephalitis
Seizure
Memory defect
Progressive Multifocal Leukoencephalopathy
Kidneys
Nephritis
Acute/chronic renal failure
End stage renal disease
Lungs
Pneumonia
Bronchitis
Respiratory failure
Eyes
Retinitis
Blindness
Liver
Chronic hepatitis
Liver cirrhosis
Hepatocellular Carcinoma
Small/Large Intestine
Colitis
Ulceration / perforation
Intestinal bleeding
Malignancy
Kaposi sarcoma
Primary Effusion
Lymphoma (PEL)

AlloVir is the Global Leader in Developing VST Immunotherapies

We develop highly innovative allogeneic, off-the-shelf VST therapy candidates designed to treat or prevent devastating viral infections and diseases.

Our Pipeline

Our allogeneic, off-the-shelf, VST therapy candidates target 12 different devastating viruses to treat or prevent life-threatening viral diseases.
view

Our Platform

Our proprietary platform develops allogeneic, off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies.
learn

Our People

Our founders have a singular vision: to serve patients at risk of the devastating consequences of severe viral infections and diseases.
meet

Cambridge

139 Main Street
Suite 500
Cambridge, MA 02142

Houston

2925 Richmond Ave
Suite 1200
Houston, TX 77098

Company

About UsContact Us617-433-2605
ContactCareers
AlloVir ©2020 All rights reserved